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p53 mutations are found in 50% of human cancers. Molecular epidemiology has shown strong 
correlations between the spectrum of p53 mutations and exposure to exogenous carcinogens. 
This spectrum is influenced quantitatively and qualitatively by various upstream genetic filters that 
modulate carcinogen activation, detoxification, and/or DNA repair. In this review, we will discuss 
how other factors such as tissue specificity, SNP of genes associated with the p53 pathway, other 
genetic alterations, or p53 mutant heterogeneity can act as a second set of downstream filters that 
also have a profound impact on the spectrum of p53 mutations.Introduction
Somatic p53 missense mutations are found in approxi-
mately 50% of human cancers (Soussi et al., 2006), but 
it is generally assumed that the p53 pathway is also 
inactivated in wild-type (WT) p53-carrying tumors via 
indirect mechanisms such as MDM2/MDMX ampli-
fication leading to p53 destabilization (Marine et al., 
2007; Brooks and Gu, 2006). An increasing number of 
studies indicate that a subset of p53 mutant proteins 
are oncogenic and actively participate in neoplastic 
transformation (Weisz et al., 2007; Peart and Prives, 
2006). These observations have several implications, 
including a possible heterogeneous clinical phenotype 
depending on whether p53 itself is mutated and on the 
site of mutations or whether p53 function is modified 
indirectly (Prives and Manfredi, 2005).
Analysis of the spectrum of p53 mutations in human 
cancer demonstrates a link between exposure to various 
types of carcinogens and the development of specific 
cancers (Hussain et al., 2000). In skin tumors, a high 
frequency of p53 mutations is observed at dipyrimidine 
sites, a molecular signature of mutagenesis by solar UV 
rays (Ziegler et al., 1994). The relationships between G 
→ T transversion and lung cancer in smokers or muta-
tion of codon 249 observed in aflatoxin B1-induced liver 
cancers are also very demonstrative (Staib et al., 2003). 
This spectrum related to carcinogen-induced adducts 
can be modulated qualitatively and quantitatively by 
various factors that act as positive or negative filters 
(Figure 1). These factors include genetic heterogeneity 
of the activation process that transforms an unreactive 
carcinogen into a form that binds DNA or heterogene-
ity of the detoxification process that eliminates the acti-
vated molecule. Similarly, SNP leading to variations in 
the activity of DNA repair genes associated with base 
excision repair (BER) or nucleotide excision repair (NER) 
have been detected in a normal population and can also 
shape the pattern of mutations (Hung et al., 2005). Many studies have focused on the analysis of these various 
upstream filters that control the transformation of a DNA 
adduct into a stable mutation. Although mutations can 
occur at multiple positions in the genome, only those 
that lead to a selective advantage for the cell will be 
identified on analysis of tumors.
So far, analyses of the spectrum of p53 mutations and 
inactivation have not taken into account another set of 
selection events that can be referred to as downstream 
filters. They include tissue specificity, functional poly-
morphisms in genes associated with the p53 pathway, or 
other oncogenic modifications occurring in the tumor. In 
this review, we will discuss how these filters can quanti-
tatively and qualitatively shape p53 alterations;how they 
can act by selecting specific mutant p53 whose proper-
ties, either loss or gain of function, are associated with 
a transforming phenotype in a given genetic and physi-
ologic environment;and how these observations can be 
translated into clinical practice.
p53 Mutant Heterogeneity
The main activity of p53 is to act as a transcription fac-
tor that binds DNA via a domain localized in the core 
region of the protein (CR; residues 100 to 300). The DNA 
sequence found in the various p53 response elements 
(p53 RE) is markedly degenerated, and the affinity of 
p53 for these various binding sites is highly heteroge-
neous, an important feature in the regulation of the p53 
response, as it imposes a hierarchy in the occupancy of 
the various p53 response elements (Qian et al., 2002; 
Inga et al., 2002). Several thousand genes have been 
shown to be directly regulated by p53, but as all these 
studies were performed in cell lines and only limited data 
are available about tissue specificity, the spatiotemporal 
response of p53 in vivo and the way in which promoter 
heterogeneity regulates p53 response remain unclear. 
Furthermore, specific cofactors, some of which have tis-
sue-specific expression, can bind to various regions of Cancer Cell 12, October 2007 ©2007 Elsevier Inc. 303
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and structural studies have shown that the CR of p53 
is highly flexible and cycles rapidly between folded and 
unfolded states (Joerger and Fersht, 2007). This fragil-
ity explains the high concentration of missense muta-
Figure 1. Shaping p53 Mutations in Human Cancer
In the exposure step, exogenous or endogenous carcinogens lead to 
the generation of a wide range of DNA adducts (blue half-ring shapes). 
These adducts are influenced qualitatively and quantitatively by sev-
eral factors, including the efficiency of the activation and detoxifica-
tion process, the affinity of the carcinogen for a given nucleotide, the 
chromatin structure, and any other factors that can modify the inter-
action of an active carcinogen with DNA. In a second step, most of 
the lesions are eliminated, but the cellular contexts (phases of the 
cell cycle, cell type) have an impact on the efficiency of DNA repair. 
In the fixation step, nonrepaired lesions are transformed into stable 
mutations (red stars) that are transmitted to daughter cells after cell 
division, resulting in three possible outcomes. First, if the mutation 
leads to a lethal phenotype, the cell dies and this counterselection 
prevents propagation of that specific alteration. A second outcome, 
which is the most common, is that the mutation does not result in 
any particular phenotype. This is the case for the majority of inter-
genic or intronic alterations, but also for certain intragenic mutations 
that target nonessential amino acid residues. Mutations targeting the 
third base of nucleotide codons also fall into this category, although it 
should be kept in mind that they can lead to defects in RNA stability 
or splicing. These “neutral mutations” are not involved in any selec-
tion process and are expanded at the rate of normal cell division of 
the original tissue. Nevertheless, if this particular cell is the target of 
a second alteration that leads to its clonal expansion, the first muta-
tion will be coselected despite the absence of associated phenotype. 
Such mutations, called “passenger mutations,” as opposed to the 
“driving mutations” that lead to clonal expansion, are quite common, 
and their frequency is related to the efficiency of the mechanism con-
trolling genetic stability. The presence of passenger mutations is a 
real problem for molecular diagnosis, as the increased throughput and 
sensitivity of genetic analysis will reveal a wide variety of passenger 
mutations that will be difficult to distinguish from true driving muta-
tions in the absence of functional assays. The third possible outcome 
for stable somatic mutations is a functional modification that results 
in a new phenotype that contributes to the neoplastic process. These 
true driving mutations are fortunately rare, but a selection process can 
be modulated by factors such as tissue specificity, the presence of 
other somatic genetic modifications, or the genetic background of the 
individual, as discussed in the text.304 Cancer Cell 12, October 2007 ©2007 Elsevier Inc.tions in the 600 bp that codes for this domain. Each 
residue in this region has been found to be mutated in 
human tumors with frequencies ranging from twice for 
infrequent mutants to more than 1000 times for hot spot 
mutants (UMD p53 database 2007_R1; http://p53.free.
fr/). Biochemical and functional studies have clearly 
demonstrated that different p53 mutants in the CR have 
a marked heterogeneity in terms of loss of structure and 
function (Soussi and Lozano, 2005). Using a library of 
2500 different p53 mutants, Kato et al. showed that, 
while hot spot mutants found in human cancers dis-
play total loss of transactivating capacity, other mutants 
retain a partial transactivation activity for a subset of tar-
get genes, leading to a wide range of possible mutant 
activities (Figure 2) (Kato et al., 2003). This observation 
is of importance, as hot spot mutants at codons 175, 
248, and 273 represent only 10% of all somatic p53 
mutations found in human tumors. It is also noteworthy 
that the fragility of the p53 core domain and susceptibil-
ity of p53 to inactivating point mutations have apparently 
not been selected against during the course of evolution, 
presumably because loss of p53 function and develop-
ment of cancer usually occur long after reproduction and 
the raising of offspring. p53 CR is also critical for inter-
actions with various cofactors. Cellular proteins such as 
Bcl-Xl or 53BP2/ASPP2 interact with WT p53, but each 
protein requires a specific set of partially overlapping 
p53 residues of the CR (Samuels-Lev et al., 2001; Mihara 
et al., 2003). p53 interaction with Bcl-Xl is specifically 
associated with transcription-independent p53-induced 
apoptosis, whereas 53BP2/ASPP binding specifically 
enhances transactivation of proapoptotic genes such as 
BAX and PIG 3 but has no effect on WAF1 (Samuels-Lev 
et al., 2001; Mihara et al., 2003). This intricate promiscu-
ity of various functions in the CR of p53 raises a num-
ber of questions concerning the interplay between the 
loss of these functions and p53 point mutations (Soussi, 
2007). Some mutants, such as R175H, are totally defec-
tive for transactivation and do not bind to 53BP2/ASPP2, 
whereas other mutants such as R273H retain a normal 
conformation and/or the capacity to bind 53BP2/ASPP2 
despite loss of their transactivation activity (Tidow et al., 
2006). Whether loss of the transcriptional transactiva-
tion function of p53 via impaired DNA binding is the only 
consequence of p53 mutations selected during tumor 
evolution remains an open question (Soussi, 2007).
The impact of the mutation on the various biologi-
cal functions of p53 is therefore an important factor 
in the selection process that will act together with the 
other filters discussed below such as tissue specificity 
or genetic background. Mouse models support these 
observations on the heterogeneity of p53 mutations. 
Knockin mice expressing two hot spot p53 mutations 
(R172H and R270H corresponding to human R175H and 
R273H, respectively) have a different phenotype from 
p53−/− mice (Olive et al., 2004; Lang et al., 2004). They 
develop a different spectrum of tumors with 50% of car-
cinomas with a high metastatic potential, while both of 
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the tumor spectra are different in mice expressing the 
two p53 mutants in the same genetic background. More 
relevant to the human population, expression of the 
same mutant p53 (R175H) in two different genetic back-
grounds results in a different tumor spectrum. How tis-
sue specificity and genetic background can contribute 
to the heterogeneity of p53 mutations both quantitatively 
(frequency of mutations) and qualitatively (diversity of 
p53 mutations) is discussed below.
Tissue Specificity
The p53 Family Network and Tissue Specificity
After discovering the p53 family members p63 and p73, 
it has become clear that all three proteins are intertwined 
in a complex crossregulation network (Yang and McKeon, 
2000; Deyoung and Ellisen, 2007). Both p73 and p63 are 
expressed as several protein isoforms that either contain 
a p53-like transactivation domain (TA isoforms) or that 
lack this domain (∆N isoforms). Each p53, p63, and 73 
isoform possesses a homologous DNA-binding domain 
and shares transcriptional targets but with opposite 
effects, as the binding of DN isoforms can block trans-
activation (Stiewe, 2007). Recent reports indicate that 
p53 is also expressed as multiple isoforms (Rohaly et al., 
2005; Bourdon et al., 2005). Although p53 expression is 
relatively ubiquitous, p73 expression and p63 expression 
are more restricted to specific tissue with various ratios of 
TA and ∆N isoforms. p63 is essential for the proliferation 
and differentiation cascade in stratified epithelia, and the 
∆N isoforms play a major role in this function (Perez and 
Pietenpol, 2007). TAp73 has a strong proapoptotic activ-
ity after DNA damage induced by drugs used in chemo-
therapy such as cisplatin or adriamycin (Yuan et al., 1999; 
Gong et al., 1999; Agami et al., 1999). It is therefore not 
surprising that deregulation of p73 or p63 will depend 
on tissue type and the ratio of the various isoforms. The 
patterns of deregulation of this p63/73 network in human 
cancer have been recently discussed in several reviews 
(Deyoung and Ellisen, 2007; Ratovitski et al., 2006). In the 
present review, we will focus on how p53 mutations can 
contribute to deregulation of this network and their rela-
tionship to tissue specificity. WT p53 does not oligomerize 
with p73, but some mutant p53 proteins bind to p73 and 
inhibit its apoptotic activity (Strano et al., 2000; Di Como 
et al., 1999). This interaction occurs specifically via the CR 
of both proteins and is restricted to structural mutant p53 
that display a change of conformation such as R249S or 
R175H (Gaiddon et al., 2001). Patients with head and neck 
SCC presenting these mutant p53 have a poor response 
to therapy associated with a lack of p73-associated apop-
tosis (Bergamaschi et al., 2003). More recently, Leong et 
al. reported that patients with the triple-negative subset of 
breast cancer (Basal-like, negative for estrogen and pro-
gesterone receptor and negative for ERBB2 amplification) 
display a high frequency of p53 inactivation, overexpres-
sion of ∆Np63 associated with inhibition of p73 apoptotic 
activity and loss of chemosensitivity (Leong et al., 2007).The p53 Response Is Tissue Specific
Analysis of p53 response in cell lines after various types 
of stress has led to the general belief that stabilization 
and activation of p53 always occur regardless of the cell 
type. However, this universal p53 response does not 
apply to whole animals (Toledo and Wahl, 2006; Soussi, 
2007). As early as 1995, Midgley et al. demonstrated a 
marked tissue-specific restriction of the p53 response 
after gamma irradiation (Midgley et al., 1995). Accumu-
lation of p53 protein following whole-body irradiation 
was associated with a strong apoptotic response in the 
spleen and thymus, while no response was observed 
in hepatocytes. Using in situ hybridization with probes 
corresponding to various p53 target genes, Fei et al. 
extended these observations and also showed strong 
tissue specificity with distinct regulation of various p53 
target genes in different tissues (Fei et al., 2002). In liver 
cells, only the Waf1 gene involved in growth arrest was 
induced, whereas none of the proapoptotic p53 target 
genes were upregulated. This observation is the inverse 
of what occurs in the spleen with specific induction of the 
proapoptotic gene Puma, whereas Waf1 or other apop-
totic genes such as Noxa or Dr5 were barely detectable. 
Another study based on transgenic mice expressing a 
lacZ reporter gene fused to the Mdm2 promoter showed 
that the pattern of p53 transcriptional response is fairly 
homogeneous in the early embryo but becomes more 
restricted with increasing embryo age and with differen-
tiation of the tissues (Gottlieb et al., 1997). A predomi-
nant p53 response after DNA damage was observed in 
Figure 2. Heterogeneity of the DNA-Binding Activity of 
Mutant p53
Due to the marked degeneracy of the p53 DNA response element, 
there is a wide variation in the affinity of wild-type p53 to DNA, with two 
extremes represented by p21/WAF1 (strong binding) and bax (weak 
binding) (vertical axis). p53 mutation generates a large number of p53 
variants with unique properties depending on the remaining affinity for 
DNA that will dictate transcription of a subset of p53-responsive genes 
(horizontal axis). Highly penetrant mutants such as R175H show a total 
loss of DNA binding with no transcriptional activity. However, the R175P 
mutant displays only a partial loss of activity with no binding to the bax 
promoter but normal binding to the p21/WAF promoter. This mutant is 
deficient for induction of apoptosis but retains wild-type activity with 
respect to induction of growth arrest. The observation that a subset 
of p53 mutants has also lost the ability to bind coactivators such as 
ASSP2 adds another level of complexity. Red and green represent wild-
type and mutant p53 activity, respectively.Cancer Cell 12, October 2007 ©2007 Elsevier Inc. 305
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shausen et al., using an inducible p53 mouse model, 
showed that p53 activation leads to specific apoptosis 
of radiosensitive tissue such as bone marrow, thymus, 
or spleen, whereas radioresistant tissues only displayed 
marked growth arrest (Ringshausen et al., 2006). All 
these observations reveal that the phenotype of a cell 
line has only a limited relation to the original tissue from 
which it is derived. Although this is not unexpected, as 
p53 is a pleiotropic stress sensor and in vitro cell culture 
in plastic dishes is quite unnatural, there is a general ten-
dency to overinterpret in vitro studies and transfection 
experiments (Toledo and Wahl, 2006).
The observed tissue-dependent p53 responses also 
raise some questions concerning whether tissue origin 
could specify the selection of particular p53 mutations. 
This issue is complex, as several confounding factors 
such as the tissue specificity of several carcinogens or 
the presence of other genetic alterations (see below) 
could influence the outcome. Nevertheless, in hepato-
cellular carcinoma, several findings support the notion 
that the R249S mutation is specifically selected in liver 
cells. Epidemiologic studies unambiguously show that 
the p53 mutation at codon 249 in liver cancer is linked 
to aflatoxin B1 (AFB1) exposure (Staib et al., 2003). In 
vitro studies exposing human liver cells to AFB1 also 
revealed the same R249S hot spot (Puisieux et al., 
1991). Two nonexclusive explanations can account for 
the high prevalence of this particular mutation in liver 
cancer. First, codon 249 may be highly sensitive to the 
mutagenic effect of AFB1, as indicated by several stud-
ies. Second, it is possible that this mutant provides a 
special growth advantage to liver cells. The second 
hypothesis is supported by several findings. (1) Although 
AFB1 binds specifically to codon 249 in vitro, it is not 
the major site of AFB1 adducts, and stronger binding 
has also been observed at other codons, such as 245 
and 248, at which mutations are found in other cancer 
types (Puisieux et al., 1991; Denissenko et al., 1998). 
The fact that these mutants are not found in liver cancer 
indicates a preferential selection for R249S. (2) Mutant 
R249S properties such as dominant-negative activity or 
increased survival effects are more potent in liver cells 
than those of other mutants (Ponchel et al., 1994). There 
is no explanation for this liver specificity of the R249S 
mutant, but a better understanding of the various gain-
of-function activities of mutant p53 and identification 
of the tissue specificity of p53 isoforms could uncover 
some novel functions for this mutant. Another asso-
ciation between tissue specificity and a particular p53 
mutant has been found in adrenal cortical carcinoma 
(ACC). In south Brazil, a germline mutation at codon 337 
(R337H) has been specifically associated with pediat-
ric ACC, with several cases in one family (Ribeiro et al., 
2001). This mutation is localized in the oligomerization 
domain but analysis of classical functions such as cell 
cycle arrest or apoptosis failed to reveal any defect of 
this mutant despite its strong association with pediatric 306 Cancer Cell 12, October 2007 ©2007 Elsevier Inc.ACC. This paradox has been resolved by structural anal-
ysis demonstrating a very high sensitivity of the R337H 
mutant to pH-induced denaturation as compared to WT 
p53 (DiGiammarino et al., 2002). As the adrenal gland is 
known to undergo extensive apoptosis during pre- and 
postnatal development, it has been postulated that an 
increased intracellular pH may lead to p53 inactivation 
and impair apoptosis specifically in these cells.
Several cancers display a very low frequency of p53 
mutation, indicating that the upstream or downstream 
p53 pathways could be impaired. Indeed, amplification of 
MDM2 is observed in sarcoma (Michael and Oren, 2003), 
and Laurie et al. recently demonstrated that amplification 
of MDMX disrupts the p53 pathway and suppresses the 
apoptotic response in retinoblastoma (Laurie et al., 2006). 
In neuroblastoma, inactivation of p53 can often occur 
through nuclear exclusion via amplification of the Parc 
protein (Nikolaev et al., 2003; Moll et al., 1995). Whether 
this high frequency of indirect p53 inactivation, predomi-
nantly observed in nonepithelial tumors, has any biologi-
cal significance remains to be analyzed.
The importance of the tissue specificity of p53 altera-
tion was recently highlighted by analysis of p53 restora-
tion in animal models (Martins et al., 2006; Ventura et al., 
2007; Xue et al., 2007). Although these three studies show 
that restoring WT p53 activity in a p53-deficient tumor 
leads to p53-dependent regression of the tumor, the out-
come differs according to tumor type. In solid tumors, p53 
induced marked growth arrest, whereas in lymphoma, 
p53 induced intense and rapid apoptosis (Martins et al., 
2006; Ventura et al., 2007; Xue et al., 2007).
p53 Mutations and Genetic Background
Exonic p53 SNP
Thirty-seven SNP have been identified in the p53 gene, 
18 of which have a frequency higher than 5% in the 
SNP500 cancer populations. The first exonic SNP dis-
covered results in a proline-to-arginine substitution at 
codon 72 (Harris et al., 1986). A striking bias in the dis-
tribution of this SNP in the human population was noted 
(Beckman et al., 1994). The frequency of the Pro/Pro 
haplotype is 16% in Scandinavian populations and 63% 
in the Nigerian population. The reason for this North/
South gradient is unknown at the present time. Residue 
72 is localized in the proline-rich domain (PRD) of the 
protein that has been associated with a regulatory func-
tion of p53 apoptosis. Transfection studies have shown 
that deletion of the PRD motif in both human and mouse 
p53 leads to specific abrogation of the apoptotic activ-
ity of p53, maintaining an intact growth arrest function 
(Walker and Levine, 1996; Sakamuro et al., 1997; Venot 
et al., 1998). These observations were not reproduced 
in MEF from mouse lacking the PRD that are unable to 
induce a cell cycle arrest but display a weak apoptotic 
activity (Toledo et al., 2006). The Arg72 p53 variant has 
a more potent proapoptotic capacity compared to the 
Pro72 variant (Dumont et al., 2003; Bergamaschi et al., 
2006). Several nonexclusive explanations have been 
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showed that a stronger interaction of the R72 variant 
with the nuclear-export protein CRM1 leads to enhanced 
nuclear export and greater accumulation in mitochon-
dria (Dumont et al., 2003). This differential interaction is 
specific to human cells and absent in mice, indicating 
that an appropriate environment is important to display 
the specificity of each human p53 variant (Phang and 
Sabapathy, 2007). Another explanation has been pro-
posed by Bergamaschi et al., who showed that iASPP, a 
specific cellular inhibitor of p53, binds to the PRD of p53 
and interacts more strongly with the P72 variant, leading 
to a more pronounced inhibitory effect on its apoptotic 
activity (Bergamaschi et al., 2006). Epidemiologic stud-
ies have been performed to determine whether this SNP 
is associated with an increased risk of cancer. Results 
of these studies are very contradictory and have not 
demonstrated any highly significant correlations, sug-
gesting that, if such an association exists, it may not be 
very strong or may be due to other as yet unidentified 
genetic factors (Pietsch et al., 2006). Similarly, analy-
sis of the prognostic value of codon 72 SNP in various 
types of cancer has not been fully conclusive. A possible 
explanation is that p53 mutant gain of function differs for 
the two p53 variants. As mentioned in a previous sec-
tion, some structural p53 mutants bind and inactivate 
the apoptotic activity of p73. The binding of mutant p53 
for p73 is stronger for the R72 variants compared to 
mutants with the Pro72 variants and generates mutant 
p53 with a strong gain of function (Marin et al., 2000; 
Bergamaschi et al., 2003). Patients with head and neck 
cancer who display these structural p53 mutants asso-
ciated with Arg72 variants have a very poor outcome. 
Therefore, two confounding effects should be consid-
ered: the lower apoptotic activity of the P72 variant and 
the enhanced gain of function of mutant p53 carrying 
the R72 polymorphism, both of which can be associated 
with a poor response to therapy or poor outcome (Figure 
3). In tumors with a high frequency of TP53 mutation, the 
R72 variant can be associated with a poor prognosis, 
whereas in tumors with a low frequency of p53 mutation, 
the low apoptotic variant P72 could be associated with a 
poorer outcome. It is unclear at the present time whether 
this model can be generalized to other settings.
A second exonic polymorphism at codon 47 chang-
ing a proline to serine has also been described (Felley-
Bosco et al., 1993). The frequency is very low, ranging 
from 0.5% to 5% in various studies. This polymorphism 
is close to serine 46, phosphorylation of which is a key 
event for the apoptotic function of p53. In vitro studies 
have shown that the S47 variant is a poorer substrate for 
S46 phosphorylation and has an impaired proapoptotic 
ability (Li et al., 2005). The clinical significance of this 
p53 variant is not known.
Functional SNP in the p53 Pathways
As discussed in a previous section, the p53 RE rec-
ognized by WT p53 is highly degenerated. The con-
sensus sequence is composed of two copies of the 5′PuPuPuC(A/T)(T/A)GPyPyPy-3′ motif separated by a 
spacer of 0 to 13 bases (Funk et al., 1992; el-Deiry et 
al., 1992). It has been clearly established that variation 
in this sequence can drastically affect the efficiency of 
transactivation (Qian et al., 2002). Several studies have 
been performed to determine whether certain natural 
SNP are present in functional p53 RE. Although a diffi-
cult challenge, using p53 as a paradigm for these studies 
is facilitated by the large number of genes regulated by 
p53 (more than a thousand), the length and degeneracy 
of the p53 RE, and our good knowledge of the p53 net-
work. Two types of analysis were used for these studies, 
a candidate gene approach performed by Bonds et al. 
and a global unbiased screening of the whole genome 
performed by Tomso et al. (Bond et al., 2004; Tomso et 
al., 2005). The first type of analysis led to the detection 
of SNP309 in the MDM2 gene (Bond et al., 2004). This 
polymorphism changes a T to G at nucleotide 309 of 
intron 1 close to the p53 RE and creates a higher-affinity 
DNA-binding site for Sp1 that leads to increased levels 
of MDM2 RNA and protein in cells. Cell lines homozy-
gous for the G allele express high levels of MDM2 and 
have an impaired p53 response after DNA damage with 
poor induction of p53 and weak p53-induced apoptosis 
(Bond et al., 2004). The frequency of individuals with the 
G/G genotype is around 1%, which is sufficiently high 
Figure 3. Complexity of p53 R72P Polymorphism
In normal cells (gray shade), p53 72R has a more potent apoptotic 
activity compared to p53 P72, suggesting that individuals with this 
SNP will have a higher cancer susceptibility compared to R72 in-
dividuals, as symbolized by the thickness of the arrows. In tumors 
(orange shade) the situation is more complex. In tumors with a low 
frequency of p53 mutations (red shade, right), p53 polymorphism P72 
is more frequent, and tumors are less sensitive to apoptosis-inducing 
treatment. On the other hand, in tumors with a high frequency of p53 
mutations (red shade, left, mutation symbolized by asterisk), mutant 
p53 encoded by the R72 allele may bind to p73 and inhibit its apop-
totic activity, and are therefore preferentially selected during tumor de-
velopment. This is supported by the observation that head and neck 
tumors bearing p53 mutations with the R72 allele are more resistant to 
chemotherapy, and these patients have a shorter survival.Cancer Cell 12, October 2007 ©2007 Elsevier Inc. 307
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Fraumeni syndrome carrying the G allele (either in the 
heterozygous or homozygous state) have an earlier 
age of tumor onset. SNP309 is found in a region of the 
MDM2 promoter that is regulated by hormonal signaling 
pathways, and recent studies have shown that the clini-
cal penetrance of this SNP is stronger in women than in 
man. The onset of cancer was found to be significantly 
earlier in patients with sarcoma, breast cancer, colorec-
tal cancer, or lymphoma (Bond et al., 2006; Bond and 
Levine, 2007). A second SNP (SNP 354) in exon 12 of 
the MDM2 gene has been recently associated with an 
increased breast cancer incidence, but its biological sig-
nificance is unknown (Boersma et al., 2006).
A specific combination of SNP in the AKT gene has 
been associated with an increased amount of AKT 
protein in cells. A large body of data indicate that the 
IGF-1-AKT survival pathway is strongly integrated in the 
p53 network (Levine et al., 2006). AKT protein phos-
phorylates and stabilizes MDM2 and downregulates 
p53 (Zhou et al., 2001; Mayo and Donner, 2001). AKT 
is negatively regulated by the phosphatase PTEN, a 
p53 response gene that is inactivated in a wide variety 
of cancers. AKT also phosphorylates and inactivates 
TSC2, which is encoded by a p53 target gene, that neg-
atively regulates the mTOR pathway after glucose star-
vation. AKT is therefore able to impair p53 response 
at multiple points in various pathways. Several SNP 
associated with variable expression of AKT have been 
Figure 4. Heterogeneity of the p53 Pathway
AKT kinase, the level of which is controlled by SNP 3-4, phosphorylates 
MDM2 protein and enhances MDM2-mediated ubiquitination and degra-
dation of p53. The level of MDM2 expression is modulated by SNP309 
SNP. p53 activity is also believed to be controlled by the Arg-Pro poly-
morphism at codon 72. In the worst case scenario, an individual with 
strong AKT activity (SNP 3-4 GG), high MDM2 expression (SNP 309 GG), 
and a p53 SNP Pro 72 with low apoptotic activity will be at high risk for 
cancer and will experience a very low response to DNA damage induced 
by chemotherapeutic agents. On the other hand, individuals with the op-
posite genotype will experience the best response. Between these two 
possibilities, multiple genotypes in these three genes and other unknown 
modifier genes will lead to a marked heterogeneity of p53 responses. 
Whether this heterogeneity contributes to cancer incidence or clinical 
status and response to treatment remains to be analyzed.308 Cancer Cell 12, October 2007 ©2007 Elsevier Inc.identified. Analysis of p53-dependent apoptosis after 
irradiation in 113 lymphoblastoid cell lines showed that 
individuals expressing high levels of AKT displayed a 
reduced apoptosis compared to individuals with lower 
AKT expression (Harris et al., 2005). Whether or not this 
population with high AKT activity will be less respon-
sive to radiotherapy or more prone to cancer has yet to 
be determined.
Using a global genome analysis, Menendez et al. iden-
tified a SNP in a putative p53 response element on the 
promoter of the FLT-1 gene (Fms-like tyrosine kinase 1). 
The FLT-1 gene encodes one of the receptors activated 
via binding of VEGF, a molecule essential for angiogen-
esis and associated with metastasis. In vitro analysis 
showed that only one of the two alleles is induced by 
p53, whereas the other is unaffected (Menendez et al., 
2006). Although no clinical data are yet available, this 
finding shows that the p53 response in a normal indi-
vidual could be highly heterogeneous. As discussed 
in a previous section, animal models also indicate that 
genetic background has a strong impact on tumor 
heterogeneity, as knockin mouse models expressing 
mutant p53 R172H (R175H in human) in different genetic 
backgrounds develop different types of tumors (Iwa-
kuma and Lozano, 2007).
Taken together, these data indicate that the p53 net-
work is genetically heterogeneous, a feature that can 
lead to a wide variation in the p53 response (Figure 4). 
Furthermore, data presented here are certainly the tip 
of the iceberg, as only a small component of the p53 
pathway has been analyzed. A multitude of SNP affect-
ing the p53 response will undoubtedly be identified in 
the near future. Understanding how all these SNP will 
collectively define tumor risk or predict tumor behavior, 
prognosis, or response to treatment will constitute an 
important challenge.
p53 Mutations and Other Tumor-Associated 
Genetic Alterations
Although p53 mutations are fairly ubiquitous and can be 
found in more than 50% of human tumors, it is now well 
known that most types of cancer harbor specific genetic 
defects such as mutations in APC in colon cancer, BRCA1 
and BRCA2 in breast cancer, and B-RAF in melanoma 
(Futreal et al., 2004). As the p53 network is closely linked to 
many other cellular pathways, it is likely that defects in any 
of these pathways, either inherited or acquired somatically, 
could influence p53 function qualitatively or quantitatively. 
We have previously discussed how PTEN and p53 muta-
tions are mutually exclusive in breast cancer.
Another example is the relationship between the 
BRCA1 and p53 pathways. BRCA1 acts both as a 
checkpoint and a DNA damage repair gene that ensures 
genome integrity (Venkitaraman, 2002). BRCA1 germ-
line mutations are associated with an increased risk of 
developing breast and ovarian carcinoma. Brca1 null 
mouse embryos die early during development, but 
this phenotype can be partially rescued by p53 defi-
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Reviewciency. Furthermore, mice carrying a partial deletion 
of the carboxy terminus of Brca1 (Brca1∆11) have a 
milder developmental defect that is totally rescued in 
a p53+/− background, but the resulting mice are prone 
to cancer (Cao et al., 2006). In breast cancer families, 
p53 mutations arise in a BRCA1-deficient background 
associated with genetic instability and DNA repair defi-
ciency, and the high frequency of p53 mutations in this 
tumor is therefore not surprising (Crook et al., 1997). 
Furthermore, the spectrum of these mutations is dif-
ferent compared to matched sporadic breast tumors of 
the same grade. Only a few mutations are localized at 
hot spot codons, and several new p53 mutations have 
been identified in BRCA1-deficient tumors (Smith et 
al., 1999). Functional analysis of these BRCA1-asso-
ciated p53 mutants shows that several of them have 
a partial defect of biological activities such as growth 
arrest or apoptosis. Other mutants behave in a man-
ner undistinguishable from WT p53 except for a weak 
transforming activity when cotransfected with H-RAS 
into rat cells (Smith et al., 1999). As animal models sug-
gest that p53 inactivation is a key step for survival of 
Brca1-deficient cells, this increased frequency of p53 
mutation in BRCA families is not unexpected, and we 
can exclude the hypothesis that these mutations are 
passenger events randomly coselected in an unstable 
genetic background. The observation that many of the 
BRCA1-associated p53 mutants retain WT function to 
a large extent is interesting. It is possible that they tar-
get a specific functional activity of p53 that has not yet 
been identified, such as specific gene transactivation 
in mammary glands or cooperation with the BRCA net-
work in DNA repair, as several proteins such as Rad51 
can bind to both p53 and BRCA1. Finally, the possibil-
ity that these mutations may affect p53’s transcription-
independent apoptosis function or affect functions of 
newly identified p53 isoforms should be considered 
(Bourdon et al., 2005; Mihara et al., 2003).
Several genetic pathways leading to cell transforma-
tion have been identified in sporadic colorectal carcino-
mas. In tumors associated with microsatellite instability 
(MSI+), the frequency of p53 mutation is low (less than 
10%) compared to other sporadic colorectal carcinomas 
(around 40%). This observation can be explained by the 
propensity of MSI+ tumors to use a pathway for tumor 
development that requires mutations in genes contain-
ing a repeated polynucleotide tract such as BAX, TGFβR, 
or IGFR (Konishi et al., 1996). It is still unclear whether 
the spectrum of p53 mutations is the same in MSI+ and 
MSI− tumors. In inflammatory breast cancer and neu-
roblastoma, the frequency of p53 mutation is low, but 
immunohistochemical and molecular analysis indicates 
accumulation of WT p53 in the cytoplasm of tumor cells. 
This abnormal localization of p53 disrupts its function 
after DNA damage (Zaika et al., 1999). Whether this par-
ticular mechanism for p53 inactivation is associated with 
a specific cell type or with other genetic defects remains 
to be determined.Prospects
This review puts into perspective several fields of 
investigation that have never been previously reviewed 
together. It should provide us with a novel working frame-
work to determine how p53 inactivation in human can-
cer should be analyzed to allow a better understanding 
of p53 pathways but also to improve our strategy for the 
clinical analysis of p53 alterations. The value of p53 muta-
tions as a clinical biomarker in various human tumors has 
been the subject of intense investigation (Soussi, 2005). 
Despite these efforts, no consensus has been reached, 
and p53 mutation analysis is not yet used in clinical prac-
tice. p53 alterations are a very complex issue, and this 
review describes how p53 mutations could be shaped 
by several factors, including genetic background, other 
tumor-associated genetic alterations, and tissue-specific 
factors. Other factors that have not been discussed here, 
including gender, ethnic background, and age, which 
could also have a major impact on p53 mutant selection, 
must also be considered. Furthermore, p53 is only one 
component of a giant surveillance network whose effi-
ciency is modulated by many other elements including 
the other members of the p53 family and several other 
signaling pathways. The essential question concerns the 
strategy used to assess p53 status in human tumors, as 
a mutation is only one of the multiple ways to impair the 
p53 pathway. Whether or not these different pathways are 
associated with the same tumor phenotype is of impor-
tance. MDM2 amplification observed in a high frequency 
of sarcomas is certainly associated with the p53-inde-
pendent oncogenic function of the MDM2 protein. As 
the main function of p53 protein is to act as a transcrip-
tion factor with a very broad spectrum of target genes, 
comparing expression profiles of tumors with different 
p53 status could be very useful to identify a specific p53 
signature, as several analyses have shown that p53 muta-
tions are associated with a specific expression signature 
in breast cancer (Sorlie et al., 2001; Miller et al., 2005). It 
has yet to be determined whether this expression signa-
ture is similar in other tissues or associated with indirect 
p53 inactivation.
The recent demonstration that therapy based on p53 
reactivation in p53-deficient tumors can lead either to 
potent apoptosis or cellular senescence, depending 
on the type of tumor, should encourage us to under-
take more global analysis of the p53 status in tumor 
cells (Martins et al., 2006; Ventura et al., 2007; Xue et 
al., 2007). Several novel strategies are already under-
way, including small molecules that activate WT p53 or 
target mutant p53 (Wiman, 2006; Vassilev, 2007). The 
effect of mutant p53 rescue by compounds such as CP-
31398 and PRIMA-1 will depend on the specific type of 
p53 mutation, as certain mutants appear less amenable 
to reactivation. Many other factors, including p53 and 
MDM2 polymorphisms and the expression of p53 family 
isoforms and other p53-regulating proteins, e.g., iASPP, 
can also affect therapeutic efficacy.Cancer Cell 12, October 2007 ©2007 Elsevier Inc. 309
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ReviewActivation of WT p53 via inhibition of p53-MDM2 bind-
ing by low-molecular-weight compounds such as Nutlin 
3 or RITA is applicable to tumors that retain WT p53 but 
also to tumors with mutant p53, and the efficiency of this 
type of therapy could be modulated by MDM2 SNP309 
(Issaeva et al., 2004; Tovar et al., 2006).
It is therefore reasonable to anticipate that analysis of 
the p53 status in human cancer will comprise a combi-
nation of SNP analysis to evaluate the patient’s individ-
ual “p53 network genotype” and precise analysis of the 
tumor status at the DNA level (p53 mutation) and/or at 
the RNA level (expression signature). Only such studies 
will be able to determine whether or not p53 will keep all 
of its promises in clinical oncology.
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